Search

Displaying results 241 - 250 of 679 in total
  1. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a m...

  2. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-sma...

  3. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type

  4. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

  5. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity. … Once bound to fibrin, it will cause fibrin accretion(clot formation) to a degree 18 folds greater than thrombin.

  6. Drug

    Echinacea

    go.drugbank.com/drugs/DB14240
    ApprovedInvestigational

    Mixtures: Herbon Wild Cherry, Herbon Sugar Free Wild Cherry
  7. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ay...

  8. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treat...

  9. Drug

    Varicella zoster vaccine (recombinant)

    go.drugbank.com/drugs/DB13924
    ApprovedInvestigational

    Recombinant zoster vaccine, manufactured as the product Shingrix by GlaxoSmithKline, is an adjuvanted non-live recombinant vaccine indicated for prevention of shingles. First approved in October 2017 by the Food and Drug Administration, ...

  10. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 will be the first drug with this novel dual mechanism of action to enter clinical development. … Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index.